The prognostic utility of protein C as a biomarker for adult sepsis: a systematic review and meta-analysis.
Biomarker
Diagnostic
Prognostic
Protein C
Sepsis
Systematic review
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
14 01 2022
14 01 2022
Historique:
received:
01
11
2021
accepted:
09
01
2022
entrez:
15
1
2022
pubmed:
16
1
2022
medline:
21
1
2022
Statut:
epublish
Résumé
Sepsis, the dysregulated host response to infection, triggers abnormal pro-coagulant and pro-inflammatory host responses. Limitations in early disease intervention highlight the need for effective diagnostic and prognostic biomarkers. Protein C's role as an anticoagulant and anti-inflammatory molecule makes it an appealing target for sepsis biomarker studies. This meta-analysis aims to assess the diagnostic and prognostic value of protein C (PC) as a biomarker for adult sepsis. We searched MEDLINE, PubMed, EMBASE, CINAHL and Cochrane Library from database inception to September 12, 2021. We included prospective observational studies of (1) adult patients (> 17) with sepsis or suspicion of sepsis that; (2) measured PC levels with 24 h of study admission with; and (3) the goal of examining PC as a diagnostic or prognostic biomarker. Two authors screened articles and conducted risk of bias (RoB) assessment, using the Quality in Prognosis Studies (QUIPS) and the Quality Assessment in Diagnostic Studies-2 (QUADAS-2) tools. If sufficient data were available, meta-analysis was conducted to estimate the standardized mean difference (SMD) between patient populations. Twelve studies were included, and 8 were synthesized for meta-analysis. Pooled analysis demonstrated moderate certainty of evidence that PC levels were less reduced in sepsis survivors compared to non-survivors (6 studies, 741 patients, SMD = 0.52, 95% CI 0.24-0.81, p = 0.0003, I Our review demonstrates that PC levels were significantly higher in sepsis survivors compared to non-survivors and patients with sepsis but not disseminated intravascular coagulation (DIC). Our evaluation is limited by high RoB in included studies and poor reporting of the sensitivity and specificity of PC as a sepsis biomarker. Future studies are needed to determine the sensitivity and specificity of PC to identify its clinical significance as a biomarker for early sepsis recognition. Trial Registration PROSPERO registration number: CRD42021229786. The study protocol was published in BMJ Open.
Sections du résumé
BACKGROUND
Sepsis, the dysregulated host response to infection, triggers abnormal pro-coagulant and pro-inflammatory host responses. Limitations in early disease intervention highlight the need for effective diagnostic and prognostic biomarkers. Protein C's role as an anticoagulant and anti-inflammatory molecule makes it an appealing target for sepsis biomarker studies. This meta-analysis aims to assess the diagnostic and prognostic value of protein C (PC) as a biomarker for adult sepsis.
METHODS
We searched MEDLINE, PubMed, EMBASE, CINAHL and Cochrane Library from database inception to September 12, 2021. We included prospective observational studies of (1) adult patients (> 17) with sepsis or suspicion of sepsis that; (2) measured PC levels with 24 h of study admission with; and (3) the goal of examining PC as a diagnostic or prognostic biomarker. Two authors screened articles and conducted risk of bias (RoB) assessment, using the Quality in Prognosis Studies (QUIPS) and the Quality Assessment in Diagnostic Studies-2 (QUADAS-2) tools. If sufficient data were available, meta-analysis was conducted to estimate the standardized mean difference (SMD) between patient populations.
RESULTS
Twelve studies were included, and 8 were synthesized for meta-analysis. Pooled analysis demonstrated moderate certainty of evidence that PC levels were less reduced in sepsis survivors compared to non-survivors (6 studies, 741 patients, SMD = 0.52, 95% CI 0.24-0.81, p = 0.0003, I
CONCLUSION AND RELEVANCE
Our review demonstrates that PC levels were significantly higher in sepsis survivors compared to non-survivors and patients with sepsis but not disseminated intravascular coagulation (DIC). Our evaluation is limited by high RoB in included studies and poor reporting of the sensitivity and specificity of PC as a sepsis biomarker. Future studies are needed to determine the sensitivity and specificity of PC to identify its clinical significance as a biomarker for early sepsis recognition. Trial Registration PROSPERO registration number: CRD42021229786. The study protocol was published in BMJ Open.
Identifiants
pubmed: 35031071
doi: 10.1186/s13054-022-03889-2
pii: 10.1186/s13054-022-03889-2
pmc: PMC8760778
doi:
Substances chimiques
Biomarkers
0
Protein C
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
21Informations de copyright
© 2022. The Author(s).
Références
J Thromb Haemost. 2020 Oct;18(10):2524-2531
pubmed: 32573898
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
J Immunol. 2008 Aug 1;181(3):2165-73
pubmed: 18641355
Intensive Care Med. 2003 Apr;29(4):530-8
pubmed: 12664219
Chest. 1993 May;103(5):1536-42
pubmed: 8486040
Lancet. 2020 Jan 18;395(10219):200-211
pubmed: 31954465
Blood. 2010 Feb 11;115(6):1121-30
pubmed: 20018912
Crit Care Med. 2004 May;32(5 Suppl):S214-8
pubmed: 15118520
Am J Physiol. 1992 Feb;262(2 Pt 1):C445-52
pubmed: 1371643
Crit Care. 2012 Aug 13;16(4):R151
pubmed: 22889177
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620902849
pubmed: 32129085
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Crit Care Explor. 2021 Apr 26;3(4):e0414
pubmed: 33928260
Am J Pathol. 2011 Nov;179(5):2637-50
pubmed: 21907691
Thromb Res. 2020 Aug;192:116-121
pubmed: 32473494
Crit Care. 2014 Jan 20;18(1):R19
pubmed: 24443891
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
Thromb Res. 2010 Aug;126(2):e88-93
pubmed: 20605193
BMC Med Res Methodol. 2014 Dec 19;14:135
pubmed: 25524443
Int J Infect Dis. 2019 Jan;78:1-7
pubmed: 30267939
Diagn Progn Res. 2019 Mar 7;3:5
pubmed: 31093575
BMJ Open. 2021 Sep 8;11(9):e050754
pubmed: 34497083
FEBS Lett. 2005 Jun 13;579(15):3310-6
pubmed: 15943976
Chest. 1992 Jun;101(6):1644-55
pubmed: 1303622
World J Surg. 2005 Jun;29(6):759-65
pubmed: 15880275
Blood. 2003 Aug 15;102(4):1499-505
pubmed: 12714492
Intensive Care Med. 2021 Nov;47(11):1181-1247
pubmed: 34599691
Crit Care Explor. 2019 Aug 01;1(8):e0032
pubmed: 32166273
Crit Care Med. 2009 Jan;37(1):96-104
pubmed: 19050610
Crit Care. 2014 Jan 13;18(1):R13
pubmed: 24410881
Crit Care. 2006;10(3):R92
pubmed: 16780598
Clin Appl Thromb Hemost. 2016 Mar;22(2):153-60
pubmed: 26072118
Blood Coagul Fibrinolysis. 2017 Sep;28(6):460-467
pubmed: 28166112
Intensive Care Med. 2017 Mar;43(3):304-377
pubmed: 28101605
J Thromb Haemost. 2011 Sep;9(9):1795-803
pubmed: 21711444
Crit Care. 2019 Mar 9;23(1):80
pubmed: 30850013
Crit Care Med. 2001 Jul;29(7 Suppl):S42-7
pubmed: 11445733
Chest. 2017 Mar;151(3):586-596
pubmed: 27876592
Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):709-725
pubmed: 29437578
J Emerg Med. 2017 May;52(5):622-631
pubmed: 27823893
Crit Care Med. 2021 Feb 1;49(2):215-227
pubmed: 33372748